Figure 5.
Main causes of virologic surveillance failures. The proportion of main causes of surveillance failures in PET (A) and LET (B) cohorts. Description of categories: no surveillance: PCR monitoring was not continued or the frequency was not as recommended; on treatment: CMV disease occurred despite antiviral treatment lasting >7 days; Ag based: patients monitored with pp65 antigenemia testing after day 100 instead of PCR testing; breakthrough: CMV diseases with undetectable viremia with adequate monitoring; threshold: detectable viremia below recommended threshold for preemptive treatment before CMV disease diagnosis, resulting in delay in antiviral treatment; positive treatment for viremia <7 days: treatment threshold was reached only within 7 days before disease onset; and no data: no information regarding PCR surveillance or start of antiviral treatment. Ag, antigen.

Main causes of virologic surveillance failures. The proportion of main causes of surveillance failures in PET (A) and LET (B) cohorts. Description of categories: no surveillance: PCR monitoring was not continued or the frequency was not as recommended; on treatment: CMV disease occurred despite antiviral treatment lasting >7 days; Ag based: patients monitored with pp65 antigenemia testing after day 100 instead of PCR testing; breakthrough: CMV diseases with undetectable viremia with adequate monitoring; threshold: detectable viremia below recommended threshold for preemptive treatment before CMV disease diagnosis, resulting in delay in antiviral treatment; positive treatment for viremia <7 days: treatment threshold was reached only within 7 days before disease onset; and no data: no information regarding PCR surveillance or start of antiviral treatment. Ag, antigen.

Close Modal

or Create an Account

Close Modal
Close Modal